← Weight Loss
Taggs compounded oral tirzepatide tablet bottle

Oral Tirzepatide

In StockWeight Loss

A daily dual GIP/GLP-1 tablet — deeper appetite control, no injection required.

Daily tablet

Dual-agonist care, without the needle.

Tirzepatide works on two gut-hormone pathways at once — GIP and GLP-1 — pairing strong appetite reduction with improved insulin sensitivity. The oral form brings that mechanism into a daily tablet, with the same clinician-led titration.

How it works

Tirzepatide activates both the GLP-1 and GIP receptors. GLP-1 quiets appetite and slows gastric emptying; GIP adds a metabolic layer that supports insulin sensitivity and how your body handles fat. Patients often describe the combination as a deeper, steadier drop in hunger than a single-agonist GLP-1.

The oral formulation uses an absorption enhancer so the peptide survives digestion. You take one tablet each morning on an empty stomach with a small sip of water, then wait about 30 minutes before eating, drinking, or taking other medications.

What to expect

  • Cadence
    One tablet daily, first thing in the morning.
  • Dosing
    Conservative start with stepwise increases as tolerance allows.
  • Timing
    Empty stomach, small sip of water, then ~30 minutes before food or other meds.
  • Response
    Strong appetite reduction that often deepens past month three.
  • Side-effect pattern
    Mild GI symptoms early in titration; a slower step-up improves tolerance.

Oral vs. injection

Oral tablet
Weekly injection
Cadence
Once daily
Once weekly
Routine
Empty stomach, 30-minute wait
Any time of day, once a week
Needles
None
Fine-gauge self-injection
Travel
Room-temperature bottle
Cold-chain vial and supplies
Best for
Needle-averse patients who want the dual mechanism
Set-and-forget weekly dosing

Who it's for

Oral tirzepatide suits adults who want the dual GIP/GLP-1 mechanism without weekly injections — including patients whose response to a single-agonist GLP-1 has plateaued.

Likely a good fit
  • Adults 18+ with a BMI of 27+ (or 25+ with a weight-related condition).
  • You want a deeper appetite response than a single-agonist GLP-1.
  • You'd prefer to avoid needles entirely.
  • You can keep a consistent morning routine on an empty stomach.
Not a fit right now
  • Personal or family history of medullary thyroid carcinoma or MEN 2.
  • History of pancreatitis, severe GI disease, or gastroparesis.
  • Currently pregnant, planning pregnancy, or breastfeeding.
  • You can't reliably dose on an empty stomach each morning.
Taggs compounded oral tirzepatide tablet bottle

Oral Tirzepatide

In StockWeight Loss

A daily dual GIP/GLP-1 tablet — deeper appetite control, no injection required.

More from Taggs

Explore the full lineup.